Nevertheless, our findings strongly suggest a critical role of the Y5R in mediating low BMI-induced neuronal NPY effects via the MAPK pathway in lung cancer progression and offer a potential therapeutic avenue to treat MAPK-driven cancers using ERK inhibitors, particularly in metastatic lung cancer patients with low BMI. The gene discussed is MAPK1; the disease is cancer.